EU/3/19/2193

About

On 21 August 2019, orphan designation EU/3/19/2193 was granted by the European Commission to Laboratorios Tillomed Spain, S.L.U, Spain, for acetazolamide for the treatment of periodic paralysis.

Key facts

Active substance
acetazolamide
Disease / condition
Treatment of periodic paralysis
Date of first decision
21/08/2019
Outcome
Positive
EU designation number
EU/3/19/2193

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Laboratorios Tillomed Spain, S.L.U
Calle Del Cardenal Marcelo Spinola 8 1º F
28016 Madrid
Spain
Tel: +34 918260953
E-mail: eu.regulatory@tillomed.co.uk

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating